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Background: Clinical beneﬁt derived from erlotinib (E) and other 
epithelial growth factor receptor (EGFR) inhibitors appears to correlate 
with a characteristic, dose-dependent skin rash. This trial sought to 
determine the feasibility of intrapatient dose escalation of E to achieve 
a maximally tolerated “target” rash (deﬁned as tolerable with minocy-
cline intervention), and to assess anticancer activity of E at the attained 
doses in patients with advanced NSCLC. Dermatological review of 
skin biopsies was performed to improve understanding of pathogenesis 
of E-associated rash.
Methods: E was administered at 150 mg/day for 21 days. E dose was 
increased to 200 mg, then in 25 mg increments every 14 days unless 
intolerable rash despite treatment with oral minocycline, if rash was 
considered intolerable by the patient, or if other, non-rash, dose-limit-
ing toxicities occurred. At ﬁrst appearance of “target” rash, biopsies 
were taken from both rash-affected and unaffected areas of skin and 
compared with baseline biopsies. Stained (hematoxylin/eosin; Giemsa; 
Gram; and McManus PAS) 4 micron sections, with matched medical 
photographs, were reviewed by a dermatologist.
Results: Forty-two patients (median age 63, [range 41-78]; 28/14 
M/F) were treated. EGFR expression (IHC ≥10% staining): positive 
29 (69%), negative 5 (12%), unknown 8 (19%). Dose-escalation to 
200-475 mg/d of E was possible in 38 (90%) patients. Median number 
of dose escalations = 2. Median duration of treatment = 9 weeks (range 
3 - 115+). Rash was experienced by all but 1 patient (98%). Worst 
grades of rash were 3, 2 and 1 in 6 (14%), 19 (45%) and 16 (38%) of 
patients, respectively (where g1=tolerable, g2=”target” (tolerable with 
intervention) and g3=intolerable despite intervention). Seven patients 
experienced non-rash DLTs: CTC g3 fatigue (3 patients); g3 headache, 
g3 infected cuticles, g3 creatinine, and g3 anorexia/g2 nausea (1 patient 
each). Manageable “target” rash was seen in 24/42 (57%). Skin biop-
sies were available for 23 patients. Altered differentiation of epithelial 
structures was observed, even in unaffected areas of skin: hair follicles 
(14/23 cases, 61%); epidermis (12/23, 52%) and sebaceous glands 
(10/22, 45%). Thickening of surface epithelium was common (17/23, 
74%). Cellular inﬁltration was seen in dermis (20/22, 91%), hair 
follicles (13/23, 56%) and sebaceous glands (10/22, 45%). Inﬁltrates 
were predominantly mononuclear, though neutrophilic inﬁltration 
was present at sites of bacterial entry/growth (6/23, 26%). Conﬁrmed 
partial responses (PR) occurred in 5 (12%) patients: all experienced 
“target” rash. Median PFS (n=42) was 2.3 months (95% CI: 1.61-4.14) 
(3.5/1.9 months by “target”/non-”target” rash). No correlation was seen 
between E dose, or EGFR expression and outcome.
Conclusion: Dose escalation of E was feasible and tolerable in most 
patients. The strategy of E dose escalation to induce rash as a means 
to improve outcome could not be validated in this study. The efﬁcacy 
reported seemed similar to E studies using standard dose. However, 
occurrence of a “target” rash appeared to correlate with improved out-
come. Biopsy analysis suggests EGFR inhibition by E alters terminal 
differentiation of keratinocytes in interfollicular epidermis, and distorts 
the pilosebaceous unit. Mononuclear inﬁltration may be linked to fol-
licular disruption. 
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Background: DMXAA (AS1404) is a small-molecule vascular 
disrupting agent in clinical trials in lung, prostate and ovarian cancers. 
A previous randomized trial in non-small cell lung cancer (NSCLC) 
compared patients receiving 1200 mg/m2 DMXAA plus carbopla-
tin and paclitaxel with patients receiving carboplatin and paclitaxel 
combination only. This showed increased response rates, time to tumor 
progression and a substantial survival advantage (median of 14.0 vs 8.8 
months) in patients receiving DMXAA. This report concerns a second 
study in NSCLC, which investigated a higher, 1800 mg/m2 dose of 
DMXAA in combination with chemotherapy. The aim was to further 
evaluate the safety and activity of DMXAA combined with chemo-
therapy in NSCLC. 
Methods: Thirty-two chemonaive patients with histologically con-
ﬁrmed stage IIIb or IV squamous or non-squamous NSCLC were 
allocated to treatment. Patients received up to 6 cycles 1800 mg/m2 
DMXAA in combination with carboplatin (AUC 6 mg/ml x min) and 
paclitaxel (175 mg/m2). Safety assessments included EKG, adverse 
events, laboratory screens and ophthalmic exams. Efﬁcacy endpoints 
were objective response rates, time to tumor progression, duration of 
response and stable disease, median and 1-year survival. 
Results: Thirty patients received 1800 mg/m2 DMXAA plus carbopla-
tin and paclitaxel, of whom 10 had squamous and 20 non-squamous 
disease. Adverse events have generally been consistent in character 
with chemotherapy effects. Among 20 serious adverse events (SAEs) 
reported to date, there have been no cardiac SAEs. No differences in 
safety have been observed between squamous and non-squamous pa-
tients. Investigators’ assessment of response (using RECIST) show that 
15 patients (50%) had a partial response, 13 (43%) had stable disease 
and 2 (7%) progressive disease. Further data from the trial will be pre-
sented, including ﬁndings on time to progression and survival.
Conclusions: The combination of 1800 mg/m2 DMXAA with carbo-
platin and paclitaxel was generally well tolerated, without evidence 
for additional DMXAA-speciﬁc side effects despite the use of a higher 
dose than that used in previous combination trials. The high response 
rate of 50% observed in this trial is consistent with that seen in the 
previous study in NSCLC when 1200 mg/m2 DMXAA was added to 
carboplatin and paclitaxel. The new data further support phase III test-
ing of DMXAA in NSCLC.
